Life Sciences
Europe Guide 2024 : Germany
Band 4
Email address
[email protected]Contact number
+49 69 9726 3939Chambers Review
Jones Day has a noteworthy practice advising clients from the pharmaceutical, biotechnology and research fields on sector-specific regulatory aspects of sizeable M&A transactions. It offers experience handling clinical trial contracts, distribution matters and strategic partnerships. The team boasts considerable patent strength covering infringement and opposition proceedings as well as enforcement. It also represents clients in life sciences litigation, such as in disputes around product labelling and misleading advertising.
Work Highlights
- Jones Day advised Cardinal Health on several local transactions as part of it USD1 billion global sale of the Cordis business to Hellman & Friedman.
Strengths
Provided by Chambers
"Jones Day is able to handle various complex and sophisticate matters for us."
"The lawyers are extremely responsive, practical and they always know the answers. You can rely on them."
"It is a very strong team, from all perspectives."
"Jones Day is able to handle various complex and sophisticate matters for us."
"The lawyers are extremely responsive, practical and they always know the answers. You can rely on them."
"It is a very strong team, from all perspectives."
Notable Practitioners
Christian Fulda is well reputed for complex international patent and unfair competition disputes as well as pan-European regulatory reviews and compliance. He also advises on commercial matters and covers the regulatory aspects of M&A transactions in the life sciences sector. His client base consists of well-known German and multinational pharmaceuticals companies, life sciences start-ups and financial investors.
"It is a pleasure to work with Christian. He always knows the answer or will quickly put me in contact with somebody who does."
"Christian is a very experienced cooperate and business attorney. He has been extremely helpful to us."
"He has such a breadth of knowledge, will always get us an answer and we have been really impressed with him."
"He is very good at understanding how USA-centric companies view regulatory compliance risk in various European jurisdictions."